Main content

    Multiple Sclerosis Clinical Trials

    Sutter Health participates in clinical trials related to Multiple Sclerosis throughout their Northern California facilities. See the listing below for an overview of current trials, including contact information. For some trials, more detailed information can be found via the title link to ClinicalTrials.gov.

    Title: A Phase II, Randomized, Double-Blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Safety and Efficacy of Abatacept in Adults with Relapsing-remitting Multiple Sclerosis (National Institute of Allergy and Infectious Diseases) Opens in a new window external site
    Description: The ACCLAIM study is testing whether the medication "abatacept" can be of benefit to patients with relapsing-remitting multiple sclerosis. Although abatacept is an investigational medication for MS, it is not a new drug - it has been approved by the FDA to treat rheumatoid arthritis.
    Investigator: Joanna Cooper, MD
    Eligibility:
    Status: Active and open to enrollment
    Location: Alta Bates Summit Medical Center
    Contact: Bethany Wexler
    510 204-1608 Email: WexlerB@sutterhealth.org



    Title: A Randomized, Double Blind, Placebo-Controlled Efficacy and Safety Study of Arbaclofen Placarbil in Subjects with Spasticity due to Multiple Sclerosis (XenoPort, Inc.)Opens in a new window external site
    Description: To evaluate the efficacy of three doses of XP19986 (arbaclofen placarbil) compared to placebo for the treatment of spasticity in subjects with multiple sclerosis (MS).
    Investigator: Joanna Cooper, MD
    Eligibility: Multiple sclerosis.
    Status: Active and open to enrollment
    Location: Alta Bates Summit Medical Center
    Contact: Jody Dosanjh 510 204-1610 Email: dosanjp@sutterhealth.org


    Title: A Phase 2, Double-Blind, Randomized, Placebo-controlled, Four-arm, Multicenter, Dose-finding study to Assess the Safety and Efficacy of Three Dose Levels of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Central Neuropathic Pain in Patients with Multiple Sclerosis (Avanir Pharmaceuticals)Opens in a new window external site
    Description: The objectives of the study are to evaluate the safety, tolerability, and efficacy of 3 doses of AVP-923 capsules in the treatment of central neuropathic pain in patients with multiple sclerosis.
    Investigator: Joanna Cooper, MD
    Eligibility: Multiple sclerosis.
    Status: Active and open to enrollment
    Location: Alta Bates Summit Medical Center
    Contact: Jody Dosanjh 510 204-1610 Email: dosanjp@sutterhealth.org


    Title: A Multicenter, Observational, Open-Label, Single-Arm Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients.
    Description: The primary purpose of this study is to determine which baseline and yearly response factors predict the clinical disease-free status response in subsequent years. The study will also clarify the effectiveness of Tysabri at establishing and maintainging this overall disease-free state.
    Investigator: Joanna Cooper, MD
    Eligibility: Patients age 18 to 45 with a diagnosis of Relapsing Multiple Sclerosis who test negative for the Anti-JCV antibodyand are treatment-naïve to disease-modifying therapyand approved to use Tysabri.
    Status: Active and open to enrollment
    Location: Alta Bates Summit Medical Center
    Contact: Bethany Wexler 510-204-1608 Email: WexlerB@sutterhealth.org


    Title: A Phase 2 Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of Tcelna in Subjects with Secondary Progressive Multiple Sclerosis.
    Description: The study will assess the efficacy and safety of Tcelna compared to placebo in subjects with Secondary Progressive Multiple Sclerosis.
    Investigator: Joanna Cooper, MD.
    Status: Active and open to enrollment
    Location: Alta Bates Summit Medical Center
    Contact: Bethany Wexler 510-204-1608 Email: WexlerB@sutterhealth.org


    > See All Neurology Clinical Trials by Condition